Available Sessions
Choose A Topic From The Drop Down Menu To Find A Date & Time That Works Best For You
Event Information
How Does It Work?
This virtual 6-session series is designed to help clinicians identify and refer patients to CAR T therapy. Expert faculty from our regional partner institutions will lead the 60-minute consulting discussion sessions. Faculty teams will present lectures on the topic of CAR T (approximately 15-20 minutes), followed by a discussion around patient cases submitted by attendees. All members of the multidisciplinary cancer team are welcome. Choose the date and time that works for you!
Why Should I Attend?
● Free CME credits available for participation - earn up to 6.0 AMA Category 1 credits!
● Opportunities to present challenging cases and receive feedback from a multidisciplinary team of specialists and peers
Meet the Experts
Northeast Presenters
Patrick Reagan,
MD
Wilmot Cancer Institute at the University of Rochester Medical Center
Rochester, NY
Kristen O'Dwyer, MD
Wilmot Cancer Institute at the University of Rochester Medical Center
Rochester, NY
South Presenters
Taha Al-Juhaishi, MD
Oklahoma University Health Stephenson Cancer Center
Oklahoma City, OK
Jennifer Holter-Chakrabarty, MD
Oklahoma University Health Stephenson Cancer Center
Oklahoma City, OK
Midwest Presenters
Abhinav Deol,
MD
Karmanos Cancer Institute
Detroit, MI
Matthew Lunning, DO, FACP
University of Nebraska Medical Center
Omaha, NE
West Presenters
Caitlin Costello, MD
UC San Diego Health Moores Cancer Center
La Jolla, CA
Catherine Lee, MD
University of Utah Transplant & Cellular Therapy Program, Huntsman Cancer Institute
Salt Lake City, UT
CME Information
Upon completion of the activity, participants should be able to:
- Summarize key aspects of approved or emerging CAR T-cell therapies for use in MM, B-ALL, and BCL/DLBCL, including development, mechanism, specific indications, and serious adverse events
- Select patients who might be appropriate for CAR T-cell therapy
- Complete timely and informative referrals to CAR T-cell therapy specialty centers
- Create a plan that reflects issues to be monitored and addressed post-CAR T-cell therapy in both the short- and long-term
